CD8A and neoplasm: Mice injected with this vaccine showed more robust antitumor ability after receiving CT26 cell shock, characterized by decreased CSCs in tumor tissue, enhanced infiltration and cytotoxicity of NK, CD4+ and CD8+ T cells, increased antibody production, and reduced immunosuppressive MDSC and Treg cells [258].